SCHEMBL30598336

SCHEMBL30598336

O=c1cc(-c2ccc(F)cc2[N+](=O)[O-])c2ccc(O)cc2o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 10/20 0.59
▸ CA9 Q16790 10/20 0.59
▸ LMNA P02545 2/20 0.59
▸ HSD17B3 P37058 7/20 0.50
▸ AKR1B1 P15121 3/20 0.50
▸ MAOB P27338 2/20 0.50
▸ ALDH2 P05091 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ SORD Q00796 1/20 0.50
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ NOD2 Q9HC29 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ GLA P06280 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ UGT1A1 P22309 1/20 0.45
▸ CASP1 P29466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26113338 1.00 CA12 (0.59) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL11502012 0.84 CA12 (0.64) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL20839408 0.80 CA12 (0.69) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL30598329 0.80 CA12 (0.63) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL30228226 0.80 CA12 (0.69) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL20848059 0.80 CA12 (0.61) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL14424515 0.78 CA12 (0.75) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL21648244 0.76 CA12 (0.74) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL26111845 0.76 CA12 (0.70) CA12CA9LMNAHSD17B3AKR1B1
SCHEMBL27903490 0.74 CA12 (1.00) CA12CA9LMNAHSD17B3AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206713-A1 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES LUNELLA BIOTECH, INC. (CA) 2025-06-26 — — US disclosed
EP-4499622-A1 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES Lunella Biotech, Inc. (CA) 2025-02-05 — — EP disclosed
CN-119072469-A 2- [ (2-Oxo-4-phenyl-2H-chromen-7-yl) oxy ] propanamide derivatives 卢内拉生物技术有限公司 2024-12-03 — — CN disclosed
WO-2023187561-A1 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES LUNELLA BIOTECH, INC. (CA) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206713-A1 2-[(2-OXO-4-PHENYL-2H-CHROMEN-7-YL)OXY] PROPANAMIDO DERIVATIVES POLRMT, TFAM, POLM CA12 4842/4885CA9 4705/4885LMNA 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback